You Call That An Offer? Facet Rejects Biogen's Hostile $355 Million Bid.
This article was originally published in The Pink Sheet Daily
Executive Summary
Having twice said no and adopting a poison pill plan, the former R&D shop at PDL will stay independent--for now.